Evidence map›Paper›PMID 36566508›Full record

ArticleAlimentary pharmacology & therapeutics2023

Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers.

Hannes Hagström, Jacinth Yan, Mats Talbäck, Anna Andreasson, Göran Walldius, Matteo Bottai, Niklas Hammar

Open access · hybridAbstract read
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinical Utility of Non-Invasive Tests for Liver Fibrosis in People Living With Alpha-1 Antitrypsin Deficiency.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hannes HagströmDivision of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8474-1759
Jacinth YanDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-2217-6977
Mats TalbäckUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Anna AndreassonDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-0203-7977
Göran WalldiusUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Matteo BottaiDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Niklas HammarUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEStockholm University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEstimating the risk for cirrhosis in the general population is complex. Existing prediction tools are in general unsatisfactory.

aimsTo explore if using commonly available biomarkers can improve the commonly used FIB-4 score in the identification of subgroups at risk of cirrhosis.

methodsWe used laboratory and clinical data on 126,925 individuals aged 35-79 years in Stockholm, Sweden, undergoing health examinations from 1985 to 1996. We used Swedish nationwide registries to ascertain 10-year cumulative incidence of severe liver disease, a composite of diagnoses corresponding to cirrhosis and its complications. We considered combinations of biomarkers associated with severe liver disease to identify subgroups with different risk profiles.

resultsDuring an average follow-up of 9.3 years, we ascertained 630 incident cases of severe liver disease (0.5%). Age, the FIB-4 score, diabetes or impaired glucose and gamma-glutamyl transferase (gGT) were the most relevant characteristics for classifying risk profiles. Using these factors, we identified 24 groups with a cumulative incidence of severe liver disease at 10 years ranging from 0.2% (age 35-65, low FIB-4, no diabetes or impaired glucose and normal gGT) to 32.1% (age 35-65, high FIB-4, diabetes or impaired glucose and high gGT).

conclusionsIdentification of subjects at increased risk of severe liver disease in the general population using the FIB-4 score can be substantially improved by adding age and specific biomarkers commonly available in the primary care setting. These parameters should be considered for inclusion in the development of future risk prediction models.

Indexed as

Liver CirrhosisNon-alcoholic Fatty Liver DiseaseBiomarkersDiabetes MellitusFollow-Up Studiesgamma-GlutamyltransferaseHumansLiverRetrospective StudiesRisk AssessmentBiomarkersgamma-Glutamyltransferasealcohol-related liver diseasecirrhosisepidemiologyNAFLDprediction

Identifiers

PMID36566508
PMCPMC10107149
OpenAlexW4312136625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.